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Cell-derived extracellular vesicles (EVs) are
involved in the development of different
pathologies including inflammatory dis-
eases and cancer (1) and have demon-
strated a promising potential for human
diagnostic (2) and therapeutic applications
(3). Constitutive secretion of these vesicles
has been described for platelets, reticulo-
cytes, dendritic cells, lymphocytes, mast
cells, intestinal epithelial cells, adipocytes,
and hepatocytes among others (4). In addi-
tion, EVs have been isolated from many
body fluids including bile (5), blood (6),
and urine (7, 8), which indicates that they
can be systemically disseminated, trans-
ferring their content/signals to cells phys-
ically separated from the secreting cell.
Depending mainly on the vesicle’s origin
and the way of vesicle-discharge from the
cells, at least two types of EVs have been
described: the endosome-derived vesicles
named “exosomes” and the plasma mem-
brane shedding vesicles referred to as
microparticles. Microparticles are a hetero-
geneous population of vesicles with a size
up 1000 nm, this group consists of vesicles
that are formed directly from plasma mem-
brane by so-called reverse budding through
membrane protrusion and fission (9). Exo-
somes, on the other hand, are a more
homogeneous vesicle population with a
size of 30–150 nm and an endocytic ori-
gin. They are formed by inward budding of
the membrane of an endocytic organelle
named multivesicular body and released
to the extracellular space by fusion of this
organelle with the plasma membrane (9).
The content of EVs and their biological
function depend on the cell-type origin. In
addition to lipids (10, 11) and proteins (10,
11), EVs give also refuge to mRNA, small
RNAs including miRNA (12–17), mtDNA
(18), and even genomic DNA (19). It is
important to highlight that this material
could be incorporated during the bud-
ding process of EVs in which a portion
of cytosol is also engulfed into the vesicles
(20) by controlled mechanisms (21, 22).
In the process of their formation, cytoso-
lic small molecules (metabolites) such as
sugars, amino acids, nucleotides, different
enzymatic cofactors, or redox regulatory
molecules among others are also included
into the vesicles. However, data regard-
ing metabolites associated with EVs are
still very limited and therefore extensive
work in this is necessary in this area. This
research effort is not only needed to map
the metabolome of EVs from different ori-
gins but also to elucidate whether there
are specific mechanisms at play for load-
ing predestined metabolites into specific
vesicles.
Extracellular vesicles are widely studied
in order to better understand their phys-
iological and pathological role as well as
to identify potential non-invasive biomark-
ers (23). Recent research indicates that EVs
have an important effect on the develop-
ment and progression of diseases such as
cancer (24) or immunological (25) dis-
eases. Some of the mechanisms of action
responsible for these effects are starting to
be unraveled. Remarkably, some publica-
tions have demonstrated the involvement
of EVs in the metabolic regulation of the
extracellular space. In this context, EVs
derived from cancer cells are able to modify
and educate the microenvironment to facil-
itate tumor growth and the establishment
of metastasis (26, 27). The importance of
EVs in keeping the normal homeostasis in
the neuronal environment is demonstrated
by the implication of EVs in the devel-
opment of Alzheimer and prion-related
diseases (28). Clayton and collaborators
have showed that EVs modify the extra-
cellular adenosine levels, which has impor-
tant implications for the activation of the
immune system (29). Taking into account
the fact that EVs from different cellular
origins and with different activities can
co-exist in a determined environment and
condition, it is clear that these recent stud-
ies only reveal the “tip of the Iceberg.”
It is therefore important to elucidate the
function of EVs in other cellular systems
to understand the complex EV network,
which will influence the final outcome
of a determined stimulus or biological
process. In the case of hepatocyte-derived
EVs, a comprehensive proteomic analysis
revealed the presence of proteins involved
in metabolizing lipoproteins, endogenous
compounds, and xenobiotics, which sug-
gests a role of exosomes in the metabolism
of these molecules (30). Our proteomics
analysis identified more than 100 differ-
ent proteins with the potential to mod-
ify the extracellular space. These include
glycolytic enzymes, fatty acid modifying-
enzymes, carboxylesterases, cytochrome
P450 monooxygenases (CYPs), and uri-
dine dinucleotide phosphate glucuronosyl
transferases (UGTs), among others. The
fact that hepatocytes are able to secrete EVs
that contain a high number of enzymes
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to extracellular compartments could also
suggest that hepatocyte-derived EVs may
play a role in the homeostasis of biofluids
including blood and bile (31, 32).
To elucidate both the metabolome of
EVs and the contribution of these vesi-
cles to hepatic and extra-hepatic metab-
olism, comprehensive technological plat-
forms are needed to integrate the final
outcome of the various activities of these
vesicles. In this context, the last-up – omic
technology, referred as metabonomics or
metabolomics, has opened new opportu-
nities to provide a global view of mech-
anisms and pathways involved in nor-
mal physiological processes as well as in
the development of diseases. Metabolomics
comprises the qualitative and quantitative
measurement of the metabolic response
to physiological or pathological stimuli.
It involves the extraction and measure-
ment of hundreds to thousands of small
molecules (<2000 Da) from cells, tissues,
or biofluids to generate metabolic pro-
files (33). Comparisons of such profiles
from different genotypes are being used
to identify specific metabolic changes lead-
ing to the understanding of physiology,
toxicology, and disease progression. The
recent developments in spectroscopic and
separation methods allow for quick and
simultaneous measurements of all classes
of metabolites in biological samples (33,
34). Advanced bioinformatics and biosta-
tistics can then be used for data min-
ing and modeling. Metabolomic profil-
ing can be performed using a number
of analytical techniques including high-
field nuclear magnetic resonance (NMR),
gas chromatography/mass spectrometry
(GC/MS), and liquid chromatography/MS
(LC/MS). Despite its excellent inter-lab
reproducibility, GCMS requires that the
majority of metabolites analyzed need
derivatization to provide volatility and
thermal stability prior to analysis (35).
While NMR demonstrates its advantages
in highly selective, quantitative and non-
destructive analysis, the sensitivity and
therefore the amount of detected metabo-
lites is low compared to MS. LC/MS,
while notoriously irreproducible, possesses
much higher sensitivity toward most meta-
bolic classes than NMR. Moreover, by
using tandem MS in combination with
high-resolution spectra, isotope distrib-
utions, and ion mobility, identification
of unknown metabolites is facilitated.
However, due to the before-mentioned
irreproducibility chemical standards are
normally necessary for absolute metabo-
lite identification. The development of
ultra-performance liquid chromatography
(UPLC) has made it possible to achieve
higher resolutions, higher sensitivities, and
rapid separations as compared to those
achieved using conventional LC (36).
Moreover, the combination of meta-
bolomics and specialized software devoted
to visualize cellular pathways offer a tool
to integrate and identify the main mech-
anisms that trigger a specific biological
process. Application of metabolomics is
growing rapidly in an increasing range
of fields such as biomarker discovery,
clinical studies, diagnostics, plants, nutri-
tion, and toxicology (37, 38). Furthermore,
metabolic biomarkers are expected to be
FIGURE 1 | Metabolic background introduced by tissue culture media in EVs analysis. Metabolites
were extracted using Cl3Cl:methanol (A) or methanol alone (B) from the pellet obtained by applying the
conventional ultracentrifugation-based exosomal purification procedure to 300 ml of
exosomes-depleted complete media incubated at 37°C during 72 h in absence of cells. Extracted
metabolites were analyzed by UPLC-MS/MS using a C18 chromatographic column. Retention time of
the metabolites along with their peak intensities are indicated in the plots. Note the elevated number of
metabolites of different chemical nature that are isolated using the exosomal purification procedure and
that need to be removed in order to determine the metabolome that is truly associated to EVs.
less species dependent than gene or protein
markers, facilitating the direct comparison
of animal models with human studies (39).
Form a practical point of view, it is
important to highlight that for the charac-
terization of the metabolome of EVs addi-
tional controls are required that are cur-
rently not included in the proteomics and
transcriptomics analysis of these vesicles.
This is exemplified by the UPLC-MS/MS
analysis of exosomes-depleted media that
has been incubated in the absence of cells
during 72-h at 37°C, and subjected to the
conventional ultracentrifugation method
currently used to isolate EVs (40). In
these control samples, substantial number
of metabolites were detected using con-
ventional solvents to extract metabolites
(Figure 1A: ClCH3:methanol, Figure 1B:
methanol). These metabolites are derived
from the tissue culture medium and need to
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be taking into account and removed from
the metabolites detected in the medium
that has been conditioned by the cells in
order to identify the metabolome truly
associated with the EVs of interest. In the
case of proteomics and transcriptomics
analyses, the background introduced by
the tissue culture media can be overcome
given that currently tissue culture media
used serum from bovine origin as major
contributor to the background. Given the
species-specific features of proteins and
nucleic acids from the media, the contami-
nating material can be discriminated from
the EVs secreted by the cells of interest. An
exemption to this latter has to be made if
a cell line of bovine origin is used for the
production of EVs; in that case a cell free
medium incubated under the same condi-
tions is also recommended for proteomics
and transcriptomics analyses.
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